Literature DB >> 32002847

Added value of myocardial blood flow using 18F-flurpiridaz PET to diagnose coronary artery disease: The flurpiridaz 301 trial.

Venkatesh L Murthy1, Edward P Ficaro2,1, Jonathan B Moody3, Alexis Poitrasson-Rivière2, Tomoe Hagio2, Christopher Buckley4, Richard L Weinberg1, James R Corbett1,5.   

Abstract

BACKGROUND: 18F-Flurpiridaz is a promising investigational radiotracer for PET myocardial perfusion imaging with favorable properties for quantification of myocardial blood flow (MBF). We sought to validate the incremental diagnostic value of absolute MBF quantification in a large multicenter trial against quantitative coronary angiography.
METHODS: We retrospectively analyzed a subset of patients (N = 231) from the first phase 3 flurpiridaz trial (NCT01347710). Dynamic PET data at rest and pharmacologic stress were fit to a previously validated 2-tissue-compartment model. Absolute MBF and myocardial flow reserve (MFR) were compared with coronary artery disease severity quantified by invasive coronary angiography on a per-patient and per-vessel basis.
RESULTS: Stress MBF per-vessel accurately identified obstructive disease (c-index 0.79) and progressively declined with increasing stenosis severity (2.35 ± 0.71 in patients without CAD; 1.92 ± 0.49 in non-obstructed territories of CAD patients; and 1.54 ± 0.50 in diseased territories, P < 0.05). MFR similarly declined with increasing stenosis severity (3.03 ± 0.94; 2.69 ± 0.95; and 2.33 ± 0.86, respectively, P < 0.05). In multivariable logistic regression modeling, stress MBF and MFR provided incremental diagnostic value beyond patient characteristics and relative perfusion analysis.
CONCLUSIONS: Clinical myocardial blood flow measurement with 18F-flurpiridaz cardiac PET shows promise for routine application.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  18F-flurpiridaz; Absolute flow; Cardiac PET; Coronary artery disease; Flow reserve; Kinetic modeling

Mesh:

Substances:

Year:  2020        PMID: 32002847     DOI: 10.1007/s12350-020-02034-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  41 in total

1.  Diagnostic value of 13N-ammonia myocardial perfusion PET: added value of myocardial flow reserve.

Authors:  Michael Fiechter; Jelena R Ghadri; Cathérine Gebhard; Tobias A Fuchs; Aju P Pazhenkottil; Rene N Nkoulou; Bernhard A Herzog; Christophe A Wyss; Oliver Gaemperli; Philipp A Kaufmann
Journal:  J Nucl Med       Date:  2012-06-29       Impact factor: 10.057

2.  Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.

Authors:  Jamshid Maddahi; Johannes Czernin; Joel Lazewatsky; Sung-Cheng Huang; Magnus Dahlbom; Heinrich Schelbert; Richard Sparks; Alexander Ehlgen; Paul Crane; Qi Zhu; Marybeth Devine; Michael Phelps
Journal:  J Nucl Med       Date:  2011-08-17       Impact factor: 10.057

3.  Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model.

Authors:  Hossam M Sherif; Stephan G Nekolla; Antti Saraste; Sybille Reder; Ming Yu; Simon Robinson; Markus Schwaiger
Journal:  J Nucl Med       Date:  2011-04       Impact factor: 10.057

4.  Single-scan rest/stress imaging: validation in a porcine model with 18F-Flurpiridaz.

Authors:  Nicolas J Guehl; Marc D Normandin; Dustin W Wooten; Guy Rozen; Arkadiusk Sitek; Jeremy Ruskin; Timothy M Shoup; Leon M Ptaszek; Georges El Fakhri; Nathaniel M Alpert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-01       Impact factor: 9.236

5.  Clinical value of absolute quantification of myocardial perfusion with (15)O-water in coronary artery disease.

Authors:  Sami A Kajander; Esa Joutsiniemi; Markku Saraste; Mikko Pietilä; Heikki Ukkonen; Antti Saraste; Hannu T Sipilä; Mika Teräs; Maija Mäki; Juhani Airaksinen; Jaakko Hartiala; Juhani Knuuti
Journal:  Circ Cardiovasc Imaging       Date:  2011-09-16       Impact factor: 7.792

Review 6.  The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease.

Authors:  Ming Yu; Stephan G Nekolla; Markus Schwaiger; Simon P Robinson
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

7.  Assessment of diagnostic performance of quantitative flow measurements in normal subjects and patients with angiographically documented coronary artery disease by means of nitrogen-13 ammonia and positron emission tomography.

Authors:  O Muzik; C Duvernoy; R S Beanlands; S Sawada; F Dayanikli; E R Wolfe; M Schwaiger
Journal:  J Am Coll Cardiol       Date:  1998-03-01       Impact factor: 24.094

8.  Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model.

Authors:  S G Nekolla; S Reder; A Saraste; T Higuchi; G Dzewas; A Preissel; M Huisman; T Poethko; T Schuster; M Yu; S Robinson; D Casebier; J Henke; H J Wester; M Schwaiger
Journal:  Circulation       Date:  2009-04-20       Impact factor: 29.690

9.  Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

Authors:  Daniel S Berman; Jamshid Maddahi; B K Tamarappoo; Johannes Czernin; Raymond Taillefer; James E Udelson; C Michael Gibson; Marybeth Devine; Joel Lazewatsky; Gajanan Bhat; Dana Washburn
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

10.  Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.

Authors:  René R S Packard; Sung-Cheng Huang; Magnus Dahlbom; Johannes Czernin; Jamshid Maddahi
Journal:  J Nucl Med       Date:  2014-07-28       Impact factor: 10.057

View more
  5 in total

1.  Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice.

Authors:  Susan Bengs; Geoffrey I Warnock; Catherine Gebhard; Ahmed Haider; Angela Portmann; Nidaa Mikail; Alexia Rossi; Hazem Ahmed; Dominik Etter; Valerie Treyer; Livio Gisler; Stefanie K Pfister; Caitlin V M L Jie; Alexander Meisel; Claudia Keller; Steven H Liang; Roger Schibli; Linjing Mu; Ronny R Buechel; Philipp A Kaufmann; Simon M Ametamey
Journal:  J Nucl Cardiol       Date:  2022-04-28       Impact factor: 5.952

Review 2.  Imaging of heart disease in women: review and case presentation.

Authors:  Nidaa Mikail; Alexia Rossi; Susan Bengs; Ahmed Haider; Barbara E Stähli; Angela Portmann; Alessio Imperiale; Valerie Treyer; Alexander Meisel; Aju P Pazhenkottil; Michael Messerli; Vera Regitz-Zagrosek; Philipp A Kaufmann; Ronny R Buechel; Cathérine Gebhard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-17       Impact factor: 10.057

Review 3.  Regulatory Agencies and PET/CT Imaging in the Clinic.

Authors:  Peter Herscovitch
Journal:  Curr Cardiol Rep       Date:  2022-08-01       Impact factor: 3.955

4.  Development, diagnostic performance, and interobserver agreement of a 18F-flurpiridaz PET automated perfusion quantitation system.

Authors:  René R Sevag Packard; C David Cooke; Kenneth F Van Train; John R Votaw; James W Sayre; Joel L Lazewatsky; Kelly M Champagne; Cesare Orlandi; Ernest V Garcia; Jamshid Maddahi
Journal:  J Nucl Cardiol       Date:  2020-09-07       Impact factor: 5.952

5.  Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of the 18F-Flurpiridaz Phase III Clinical Trial.

Authors:  René R Sevag Packard; Joel L Lazewatsky; Cesare Orlandi; Jamshid Maddahi
Journal:  J Nucl Med       Date:  2020-11-27       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.